The ErbB2 receptor tyrosine kinase (RTK) has been intensely pursued as a cancer therapy target due to its association with breast cancer. In this study we used the HC11 mammary epithelial cell line to develop an orthotopic, ErbB2-driven tumor model for testing ecacy of anti-cancer compounds. HC11 cells were infected with a retrovirus encoding oncogenic NeuT, the rat homolog of ErbB2. Drug-selected populations were introduced into mammary fat pads of Balb/c syngeneic mice cleared of host tissue. The majority of glands injected with HC11-NeuT cells developed mammary tumors which appeared after a 3 ± 4 week latency period and grew rapidly. HC11 cells infected with the control retrovirus showed no tumor growth after injection. Tumor-bearing mice were used to compare the in vivo ecacy of two anti-cancer agents: PKI166, a kinase inhibitor selective for EGF receptor and ErbB2, and Taxol 1 , a microtubule assembly blocker. PKI166 inhibited NeuT-induced mammary tumor growth in a dose-dependent manner and at a dose below the maximum tolerated dose (MTD) was signi®cantly more inhibitory than Taxol 1 at its MTD (57% vs 25% tumor regression). Importantly, there was a dose-dependent decrease in the phosphotyrosine content of NeuT isolated from PKI166-treated, tumor-bearing mice, providing a mechanistic link between kinase inhibition and its antitumor activity. Thus, implantation of genetically manipulated HC11 cells into mammary glands appears to be an excellent model for studying eects of anti-cancer agents in an orthotopic site. Oncogene (2001) 20, 5459 ± 5465.
The ErbB2 receptor tyrosine kinase (RTK) has been intensely pursued as a cancer therapy target due to its association with breast cancer. In this study we used the HC11 mammary epithelial cell line to develop an orthotopic, ErbB2-driven tumor model for testing ecacy of anti-cancer compounds. HC11 cells were infected with a retrovirus encoding oncogenic NeuT, the rat homolog of ErbB2. Drug-selected populations were introduced into mammary fat pads of Balb/c syngeneic mice cleared of host tissue. The majority of glands injected with HC11-NeuT cells developed mammary tumors which appeared after a 3 ± 4 week latency period and grew rapidly. HC11 cells infected with the control retrovirus showed no tumor growth after injection. Tumor-bearing mice were used to compare the in vivo ecacy of two anti-cancer agents: PKI166, a kinase inhibitor selective for EGF receptor and ErbB2, and Taxol 1 , a microtubule assembly blocker. PKI166 inhibited NeuT-induced mammary tumor growth in a dose-dependent manner and at a dose below the maximum tolerated dose (MTD) was signi®cantly more inhibitory than Taxol 1 at its MTD (57% vs 25% tumor regression). Importantly, there was a dose-dependent decrease in the phosphotyrosine content of NeuT isolated from PKI166-treated, tumor-bearing mice, providing a mechanistic link between kinase inhibition and its antitumor activity. Thus, implantation of genetically manipulated HC11 cells into mammary glands appears to be an excellent model for studying eects of anti-cancer1
Introduction
The development of target-speci®c anti-cancer therapeutics will be aided by improved models for determining in vivo ecacy. With this in mind, our goal has been to generate an orthotopic tumor model to test therapeutics targeted to receptor tyrosine kinases (RTKs). The model had to ful®l certain criteria, namely, reproducibility and dependence upon an oncogene which is relevant for breast cancer. For our purposes, mammary cancer driven by the ErbB2 RTK appeared to be the best choice. The c-erbB2 gene is ampli®ed and overexpressed, in a high percentage of human breast tumors (Slamon et al., 1987; Berger et al., 1988) and elevated levels of ErbB2 correlate with an unfavorable patient prognosis (Hynes and Stern, 1994) . Furthermore, the ErbB2 RTK has been clinically validated as a cancer therapy target (Cobleigh et al., 1999) .
MMTV-NeuT transgenics, expressing the rat homolog of ErbB2, develop mammary cancer (Muller et al., 1988) and oer one possibility for testing anti-cancer agents in an orthotopic site. In fact, tumor-bearing MMTV-NeuT transgenics have been examined for response to a Ras-directed farnesyl-protein transferase inhibitor (FTI) (Norgaard et al., 1999) . These mice, however, have certain limitations including long tumor latency and sporadic kinetics of tumor formation, making it dicult to obtain large numbers for controlled testing. With these problems in mind, we turned to the mammary gland reconstitution system which allows the introduction of genetically manipulated cells into mammary glands cleared of host tissue, so-called cleared fat pads (CFPs) (DeOme et al., 1959; Smith, 1996; Medina, 1996) . We reasoned that by introducing the NeuT oncogene into mammary epithelial cells and subsequently transplanting the cells into CFPs it might be possible to rapidly induce tumors in a suciently large number of mice to be useful for screening purposes.
For these studies we used the HC11 mammary epithelial cell line. HC11 is a clonal derivative of the COMMA-D cells which were isolated from mammary tissue of pregnant Balb/c mice (Danielson et al., 1984; Ball et al., 1988) . Subcutaneous injection of oncogene transformed HC11 cells into nude mice (Hynes et al., 1990) and into syngeneic Balb/c hosts (NE Hynes, unpublished results) results in tumor growth. In the experiments presented here, we show that the HC11 cells can be used in an orthotopic tumor model. HC11 cells genetically engineered to express NeuT consis-tently yielded tumors following their injection into CFPs of Balb/c mice. Mammary tumors appeared rapidly, 3 ± 4 weeks after transplantation. Tumorbearing mice have been used to show that the novel ErbB family kinase inhibitor PKI166 (Bruns et al., 2000) , is a more potent anti-cancer agent than Taxol 1 .
Results

Mammary gland reconstitution with HC11 cells
The mammary gland reconstitution model allows introduction of mammary cells into CFPs of female hosts where the injected cells retain their original characteristics. Primary mammary epithelial (PME) cells, subject to endogenous hormonal in¯uences of the host, grow to form a normal mammary gland, while mammary tumor cells retain their transformed properties (DeOme et al., 1959; Smith, 1996; Medina, 1996) . Thus, reconstitution in the mammary fat pad presents itself as an attractive possibility for developing an orthotopic tumor model.
The HC11 mammary epithelial cell line has preserved characteristics of mammary development (Ball et al., 1988; Hynes et al., 1990; Chammas et al., 1994) and, we reasoned, might oer certain advantages over PME cells for this model. HC11 cells grow continuously in culture and can easily be infected with retroviruses. Furthermore, they possess two mutant p53 alleles and thus, are negative for WT p53 (Merlo et al., 1994) . Based upon the results with transgenic strains which show a more rapid onset of mammary tumors in a p53 mutant background (Li et al., 1997, discussed in Murphy and Rosen, 2000) , we speculated that transformed HC11 cells might also form tumors more rapidly than transformed PME cells.
NeuT driven tumorigenesis
Oncogenic activation of the ErbB2 RTK occurs either by overexpression, as observed in human tumors (Slamon et al., 1987; Hynes and Stern, 1994) , or by point mutation, as was detected in the NeuT oncogene isolated from rat neuronal tumors (Bargmann et al., 1986) . In both cases the receptor is constitutively activated in a ligand-independent manner due to spontaneous dimerization. We chose NeuT for these experiments since there is a wealth of data on the transgenic MMTV-LTR NeuT mice (Muller et al., 1988; Siegel et al., 2000) . Most importantly, mammary tumors arising in this strain are histologically comparable to human tumors overexpressing ErbB2 (Cardi and Wellings, 1999; Cardi et al., 2000) .
HC11 cultures were infected with the pBabe purocontrol and the pBabe puro-NeuT retrovirus and puroselected populations were injected into CFPs of Balb/c mice. Mammary tumors developed in 79% (281/356) of the pBabe puro-NeuT transplanted glands with a 3 ± 4 week latency. At this time the average tumor volume was 80 ± 160 mm 3 , and during the following 3 weeks the volume increased 5 ± 6-fold. Mammary glands transplanted with control HC11 cells did not give rise to palpable tumors.
Whole mount analysis was performed on selected mammary glands taken 3 and 6 weeks after injection of the cells. HC11 cells have previously been shown to give rise to some normal epithelial structures following implantation, however, they are incapable of ®lling the fat pad (Humphreys and Rosen, 1997) . Our results were very similar in that the HC11-puro control cells only produced small areas of growth (Figure 1b and d). Implanted HC11-NeuT cells produced tumors which were approximately 5 and 11 mm in length, respectively, at 3 and 6 weeks, documenting their rapid growth (Figure 1a and c). (Due to its large size, part of the tumor shown in Figure 1c was lost during preparation of the wholemount). There have been reports of sporadic tumors in CFPs implanted with HC11 control cells (quoted in Humphreys and Rosen, 1997) . Over an 18 week observation period, however, we have not detected tumors in more than 30 glands injected with HC11-puro control cells. Thus, within the time frame of 4 ± 5 months, the risk of spontaneous tumors arising from transplanted HC11 cells appeared to be neglible, which was an important criterion for further development of the orthotopic tumor model. (Cardi and Wellings, 1999; Cardi et al., 2000) . NeuT induced tumor growth is more sensitive to the ErbB kinase inhibitor PKI166 than to Taxol   1 The rapidity and consistency of HC11-NeuT tumor induction in the CFP model were ideal conditions for testing the antitumor compounds PKI166 and Taxol
PKI166 is an inhibitor of the pyrrolo-pyrimidine class which is selective for ErbB kinases (Bruns et al., 2000) . More speci®cally, PKI166 inhibits the in vitro EGFR and ErbB2 enzymatic activity with an IC 50 of 1.7 and 7 nM, respectively (Bruns et al., 2000 and D Fabbro, Novartis, personal communication Figures 3 and 4 , respectively. Animals treated with high dose PKI166 showed signi®cantly more tumor regression than those treated with the lower dose: 57% (8/14) vs 17% (2/12). No response was seen in 21% (3/14) and 75% (9/12) of the high dose vs the low dose group. The remaining tumors remained stable during the 3 week treatment period (Figure 3 ). There was also a clear antiproliferative eect of PKI166 at the histological level. Decreased tumor size was accompanied by a decrease in mitotic ®gures. There was also a marked shrinkage of the central necrotic area and an increased ®brosis in the tumor stroma. PKI166 also induced morphological dierentiation since in the treated mice tumor cells were aggregated in polarized clusters (DR Roth, Novartis, personal communication). The results with Taxol 1 were very similar to those with low dose PKI166, i.e., 25% (3/ 12) of the tumors regressed on Taxol 1 while 67% (8/ 12) did not respond to the treatment (Figure 4 ). This response, however, was not signi®cant.
In order to provide a mechanistic link between the eects of PKI166 on tumor growth and its eects on ErbB kinase activity, we examined the phosphorylation status of NeuT after treatment with the inhibitor. HC11-NeuT infected cells were treated for 3 h with 0.5, 5 and 50 mM PKI166 and cell lysates were prepared. A Western analysis carried out on immunoprecipitated NeuT revealed that there was a dose dependent decrease in its phosphotyrosine content (Figure 5a ). To examine the in vivo ecacy of PKI166, mice bearing HC11-NeuT-induced mammary tumors were treated daily for 7 days with 50 or 100 mg kg 71 PKI166 or with vehicle control. Results from a Western analysis revealed that there was a signi®cant dose-dependent decrease in the phosphotyrosine content of NeuT isolated from inhibitor-treated, tumor-bearing mice (Figure 5b ). These results demonstrate for the ®rst time that PKI166 blocks the kinase activity of ErbB2/ ). The treatment continued over 3 weeks when the experiment was terminated. The mice were catagorized into the groups regression, stable disease or non responder, as de®ned in Materials and methods
NeuT in an orthotopic tumor model. Furthermore, these results provide the mechanistic link between the block in NeuT kinase activity and the anti-tumor activty of PKI166.
Discussion
Identi®cation of the molecular alterations contributing to human breast cancer has permitted the design of therapeutics targeted to proteins involved in the malignancy. The antibody Herceptin TM was developed as an anticancer agent based upon its inhibition of ErbB2-overexpressing breast tumors, and as such, is one of the best examples of this rational approach (Cobleigh et al., 1999) . Speci®c kinase inhibitors are also ®nding increased use in the treatment of human cancer (Druker and Lydon, 2000; Fabbro et al., 2000) . Ideally, the molecular identi®cation of proteins causally involved in cancer should go hand in hand with the development of appropriate systems for screening the ecacy of anticancer agents. This study makes three important contributions to this area. Firstly, we demonstrate the feasibility of using the mammary fat pad transplantation technique to consistently and rapidly induce mammary tumors driven by an oncogene implicated in breast cancer. Secondly, we establish that the HC11 cells can be routinely used in this model. Finally, we show for the ®rst time that an inhibitor speci®c for the EGFR family of kinases shows ecacy in an ErbB2/NeuT induced mammary tumor model.
Transgenic mammary tumor models developed by germ line transmission have been extremely important for mammary cancer biology. The mammary gland reconstitution technique oers an additional possibility for testing the phenotype of genetically altered mammary cells in their normal in vivo setting. Although there are some studies where retrovirally infected PME cells were implanted into CFPs to study oncogene induced eects in the gland (Edwards et al., 1992; Bradbury et al., 1993) , the technique has not been widely employed. In the experiments by Edwards and collaborators, NeuT infected PME cells only sporadically induced malignant tumors, perhaps because only a fraction of the implanted cells were infected (Bradbury et al., 1993) . We also examined a small number of mice implanted with PME pBabepuro NeuT infected cells. Compared to the tumor latency of 3 ± 4 weeks after injection of HC11-NeuT cells, the PME-NeuT cells sporadically produced tumors after 8 weeks (A M-L Wong, unpublished observations). The more rapid tumor induction with the HC11-NeuT cells supports our hypothesis that lack of WT p53 might shorten the latency to tumor formation, although this remains to be proven using, e.g., PME cells from p53 null mice.
Considering the ease of generating HC11 cells expressing ectopic proteins, this orthotopic tumor model may prove amenable not only for screening purposes, but also more generally for studying mammary cancer. To date, some of the Wnt proteins have been examined in this model, where it was observed that only HC11-Wnt7b and not HC11-Wnt 1 or -Wnt 2 cells gave rise to mammary tumors (Humphreys and Rosen, 1997) . It will also be interesting to see if the morphological dierence . The treatment continued over 3 weeks when the experiment was terminated. The mice were categorized into the groups regression, stable disease or non responder, as de®ned in Materials and methods or vehicle control (lanes 1 ± 3, respectively). Neu was immunoprecipitated from cell-or tumor lysates and the Western blots were analysed using a phosphotyrosine speci®c antibody (P-Tyr). Blots were stripped and reprobed to detect Neu. IP, immunoprecipitation; WB, Western blot observed between various transgenic strains of mammary cancer (Cardi and Wellings, 1999; Cardi et al., 2000) can be recapitulated in the HC11 CFP mammary reconstitution model. Finally, screening of human breast tumor DNAs suggests that speci®c combinations of oncogenes synergize during cancer development (Cuny et al., 2000) . In comparison to the lengthy time needed to generate bi-transgenics, the HC11 CFP model oers the possibility to rapidly examine oncogenic interactions and the eects which they might have on therapeutic response. Of course we are aware that the HC11 cells will never replace PME cells for various reasons, the important one being their inability to generate a normal mammary gland upon reimplantation in CFPs. Furthermore, while we know that HC11 cells lack p53, they may have accumulated additional unknown genetic alterations during the process of immortalization. Nevertheless, the consistency and rapidity of tumor formation made them most suitable for the experiments presented in this study.
How do the HC11-NeuT induced tumors compare to those arising in the well studied MMTV-NeuT transgenic model? With respect to histology the tumors are very similar, as we show here. Approximately 45% of the MMTV-NeuT transgenics which develop mammary tumors also show lung metastasis (Guy et al., 1992) . In an attempt to determine whether or not HC11-NeuT implants metastasize, we removed the primary HC11-NeuT-induced tumors from the mammary glands 4 weeks after implantation, a time when the surgical procedure caused minimal trauma for the mice. When the animals were sacri®ced 3 months later there was no evidence of metastasis in any organ (R Brandt, unpublished observation). Considering that in the MMTV-NeuT transgenic model lung metastases were only found after 8 months, it might be necessary to leave our mice longer. However, it is also possible that within the 4 week implantation period, HC11-NeuT cells have not had sucient time to undergo alterations necessary to promote metastasis. In this respect, the long latency period in the MTV-NeuT transgenic model might be more permissive for accumulating mutations which make the cells metastatic.
The experiments presented here establish the utility of the genetically manipulated, reconstituted mammary gland as a model for testing anticancer agents. Our results show that PKI116, a dual EGFR/ErbB2 kinase inhibitor, blocks NeuT induced mammary cancer. The extensive clinical data showing the antitumor activity of adjuvant paclitaxel in women with metastatic breast disease (discussed in Gianni, 1997) prompted us to compare its eects with those of PKI166, a new anticancer agent. Regression induced by near MTD doses of Taxol 1 (25%) was closer to that achieved with the low dose of PKI166 (17%); however, Taxol 1 was less potent as compared to the high dose of PKI166 (57%) which was administered at slightly less than the MTD. These results suggest that the PKI166 kinase inhibitor might be more eective than Taxol 1 in blocking ErbB2/Neu induced tumor growth. Interestingly, in a small pilot study where paclitaxel was evaluated in primary treatment of patients with advanced breast cancer, it is perhaps noteworthy that 17% (1/6) showed complete regression (Rees et al., 1996) , a response similar to that observed in the HC11-NeuT mammary tumor model.
To our knowledge this is the ®rst study showing that an antitumor agent speci®c for ErbB RTKs blocks the growth of an ErbB2/Neu induced mammary tumor. It is worthwhile mentioning here that MMTV-Neu transgenic mice have been tested with the FTI L-744,832. Although this inhibitor caused regression of MMTV-Ras induced mammary tumors, it had no signi®cant eect on MMTV-Neu induced mammary tumor growth (Barrington et al., 1998) , pointing to the speci®city of ErbB2/Neu driven mammary cancer.
It is interesting to speculate on the mechanism underlying the inhibitory eects of PKI166. It is becoming increasingly clear that there is a high level of cooperation between members of the ErbB receptor family, both in the normal cellular setting and in cancer (Olayioye et al., 2000) . In fact, there is a good possibility that multiple ErbB receptors are active in the HC11-NeuT model. Pertinent to this discussion is the ®nding that mammary tumors derived from MMTV-Neu transgenic mice exhibit overexpression of endogenous EGFR (DiGiovanna et al., 1998) . Furthermore, considering that many of the EGF-related ligands are expressed in the mammary gland (Schroeder and Lee, 1998) and that HC11 cells produce biologically active TGFa (Hynes et al., 1990) , it is very likely that the EGFR is active in the HC11-NeuT induced tumors. Thus, it is tempting to speculate that PKI166 blocks tumor growth by inhibiting both receptors, something we will examine in the future.
Material and methods
Cell lines and retroviral infection
HC11 cells were grown in RPMI-1640 supplemented with 10% fetal calf serum (FCS), 10 ng/ml EGF (recombinant human, Sigma) and 5 mg/ml insulin (Sigma). BOSC-23 viral packaging cells were propagated in Dulbecco's modi®ed Eagle's medium with 10% FCS. All culture media were supplemented with penicillin and streptomycin. HC11 cells were infected with the pBabe-puro retrovirus (Morgenstern and Land, 1990) encoding the oncogenic NeuT (Bargmann et al., 1986 ) (pBabepuro NeuT) or control pBabe-puro. High-titer, helper-free recombinant retroviruses were produced from BOSC-23 cells which were transiently transfected with plasmid DNA, using the CaPO 4 technique (Pear et al., 1993) . HC11 cells were infected by exposure to ®ltered conditioned medium from 24 ± 48 h transfected BOSC-23 cultures, in the presence of 40 mg/ml polybrene. One day later the medium was replaced with fresh virus-containing medium. Cells were trypsinized, split 1 : 2 into HC11 growth medium containing 0.75 mg/ml puromycin and selected for 3 ± 4 days. One day before harvesting, the cells were cultured in the absence of puromycin, then trypsinized cells were washed, resuspended at 0.5 ± 1610 6 cells/10 ml PBS and implanted in CFPs as below.
Mammary gland transplantation
All experiments were performed with Balb/c mice (BRLFuÈ llinsdorf, Switzerland) which were maintained and handled according to the Swiss guidelines for animal safety. Transplants were performed on 3 week-old females whose inguinal fat pads had been cleared of host mammary gland cells (DeOme et al., 1959) . The anesthetized mouse was pinned on a cork board and scrubbed with 70% ethanol. An inverted Y-shaped incision was made along the abdominal midline and laterally between the fourth and ®fth nipples midway down each hind leg. The resulting skin¯aps, with the fourth mammary gland attached, were separated from the body wall by blunt dissection and the free edge was pinned to the cork board, exposing the nipple area and most of the fourth fat pad. The nipple area, the large blood vessel ventral to the lymph node and the area between the fourth and ®fth pads were cauterized. The area containing the growing gland elements, including the adjacent portion of the fat pad and the surrounding loose connective tissue, was excised with ®ne scissors. The remaining portion of the fat pad with its circulation intact was ready to receive a transplant of 0.5 ± 1610 6 cells. Both inguinal fat pads were used for pBabepuro NeuT infected HC11 cells. Tumors developed in 79% (281/356) of the transplanted glands and in the majority (75%), tumors were found at both sites of injection.
Wholemounts and immunostaining
Glands were wholemounted, ®xed a minimum of 2 days in Carnoy's ®xative (ethanol: chloroform: glacial acetic acid (6 : 1 : 1)), defatted in ethanol 2 days, rehydrated and stained with Carmine Red. Tumor material was ®xed in formaldehyde containing 1% acetic acid and embedded for haematoxylin and eosin staining.
In vivo efficacy studies on PKI166 and Taxol   1 Tumors were detected by palpation 3 weeks after injection of the HC11-NeuT cells. Only those mice bearing tumors which grew 10% over the next 7 days were selected for ecacy studies which were begun at 4 weeks. For in vivo administration, PKI166 was dissolved in DMSO/0.5% Tween 80 and then diluted 1 : 20 in water. PKI166 was administered at 33 and 100 mg kg 71 day
71
, p.o. by gavage, ®ve times per week. Paclitaxel (Taxol 1 ) was used in the clinical formulation diluted four times with water. Taxol 1 was administered i.v. at the MTD of 15 mg kg 71 three times per week. Freshly prepared compounds were administered over a 22-day period. A minimum of 10 tumors per group were used in all experiments. Tumor volumes were determined three times per week according to the formula: Length6Diameter 2 6l/6. For statistical analyses the animals were assigned to three groups: non-responders, tumor volume increased 530%; stable disease, tumor volume changed 530%; tumor regression, tumor volume decreased by 430%. The P-values were calculated comparing each treatment group with the control using the Crochan-Mantel-Hansel (CMH) test. The P-values were ranked and the Holm's procedure used to adjust for multiple comparisons and to identify those groups that were statistically dierent from controls (P50.025).
Comparison between treatments was accomplished by the CMH test but adjustment for multiple comparisons was not made. Calculations were conducted using SAS.
